The dystrophin-glycoprotein complex in brain development and disease

Trends in Neurosciences

Volumn 35, Issue 8, 2012, Pages 487-496

  Waite, Adrian ^a   Brown, Susan C ^b   Blake, Derek J ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ROYAL VETERINARY COLLEGE   (United Kingdom)

Author keywords

Cognitive impairment; Dystonia.; Dystroglycan; Dystrophin; Muscular dystrophy; Neuronal migration

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; ALPHA DYSTROGLYCAN; BETA DYSTROGLYCAN; DYSTROBREVIN; DYSTROPHIN; FUKUTIN; GLYCOPROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MANNOSYLTRANSFERASE; N ACETYLGLUCOSAMINE; NEUROLIGIN; SARCOGLYCAN; SYNTROPHIN;

ATTENTION DEFICIT DISORDER; AUTISM; BECKER MUSCULAR DYSTROPHY; BRAIN CORTEX; BRAIN DEVELOPMENT; BRAIN DISEASE; CHROMOSOME VARIANT; COMPARATIVE STUDY; CYTOSKELETON; DUCHENNE MUSCULAR DYSTROPHY; DYSCALCULIA; DYSGRAPHIA; DYSLEXIA; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE MUTATION; GLIA; HIPPOCAMPUS; HUMAN; INTELLIGENCE QUOTIENT; MUSCULAR DYSTROPHY; NERVE CELL; NERVE CELL PLASTICITY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PURKINJE CELL; REVIEW; SKELETAL MUSCLE; SYNAPSE; WALKER WARBURG SYNDROME; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; BRAIN; BRAIN DISEASES; DYSTROPHIN-ASSOCIATED PROTEIN COMPLEX; GLYCOPROTEINS; HUMANS;

EID: 84864029027     PISSN: 01662236     EISSN: 1878108X     Source Type: Journal    
DOI: 10.1016/j.tins.2012.04.004     Document Type: Review

References (116)

1. McNally E.M., Pytel P. Muscle diseases: the muscular dystrophies. Annu. Rev. Pathol. 2007, 2:87-109.
2. Blake D.J., Kroger S. The neurobiology of Duchenne muscular dystrophy: learning lessons from muscle?. Trends Neurosci. 2000, 23:92-99.
3. Mehler M.F. Brain dystrophin, neurogenetics and mental retardation. Brain Res. Brain Res. Rev. 2000, 32:277-307.
4. Haenggi T., Fritschy J.M. Role of dystrophin and utrophin for assembly and function of the dystrophin glycoprotein complex in non-muscle tissue. Cell Mol. Life Sci. 2006, 63:1614-1631.
5. Masaki T., Matsumura K. Biological role of dystroglycan in Schwann cell function and its implications in peripheral nervous system diseases. J. Biomed. Biotechnol. 2010, 2010:740403.
6. Duchenne G. Recherches sur la paralysie musculaire pseudo-hypertrophique, ou paralysie myosclerosique. Arch. Gen. Med. 1868, 11:5-25. 179-209, 305-321, 421-443, 552-588.
7. Cotton S.M., et al. Association between intellectual functioning and age in children and young adults with Duchenne muscular dystrophy: further results from a meta-analysis. Dev. Med. Child Neurol. 2005, 47:257-265.
8. Desguerre I., et al. Clinical heterogeneity of Duchenne muscular dystrophy (DMD): definition of sub-phenotypes and predictive criteria by long-term follow-up. PLoS ONE 2009, 4:e4347.
9. Hinton V.J., et al. Poor verbal working memory across intellectual level in boys with Duchenne dystrophy. Neurology 2000, 54:2127-2132.
10. Wu J.Y., et al. Association of Duchenne muscular dystrophy with autism spectrum disorder. J. Child Neurol. 2005, 20:790-795.
11. Hendriksen J.G., Vles J.S. Neuropsychiatric disorders in males with Duchenne muscular dystrophy: frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive-compulsive disorder. J. Child Neurol. 2008, 23:477-481.
12. Gai X., et al. Rare structural variation of synapse and neurotransmission genes in autism. Mol. Psychiatry 2012, 17:402-411.
13. Billard C., et al. Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy. Dev. Med. Child Neurol. 1998, 40:12-20.
14. Miranda R., et al. Reorganization of inhibitory synapses and increased PSD length of perforated excitatory synapses in hippocampal area CA1 of dystrophin-deficient mdx mice. Cereb Cortex 2009, 19:876-888.
15. Perronnet C., Vaillend C. Dystrophins, utrophins, and associated scaffolding complexes: role in mammalian brain and implications for therapeutic strategies. J. Biomed. Biotechnol. 2010, 2010:849426.
16. Sbriccoli A., et al. Architectural changes of the cortico-spinal system in the dystrophin defective mdx mouse. Neurosci. Lett. 1995, 200:53-56.
17. Carretta D., et al. Spatial analysis reveals alterations of parvalbumin- and calbindin-positive local circuit neurons in the cerebral cortex of mutant mdx mice. Brain Res. 2004, 1016:1-11.
18. Carretta D., et al. Cortical and brainstem neurons containing calcium-binding proteins in a murine model of Duchenne's muscular dystrophy: selective changes in the sensorimotor cortex. J. Comp. Neurol. 2003, 456:48-59.
19. Minciacchi D., et al. Alterations of the cortico-cortical network in sensori-motor areas of dystrophin deficient mice. Neuroscience 2010, 166:1129-1139.
20. Jagadha V., Becker L.E. Brain morphology in Duchenne muscular dystrophy: a Golgi study. Pediatr. Neurol. 1988, 4:87-92.
21. Lv S.Y., et al. Decreased gray matter concentration and local synchronization of spontaneous activity in the motor cortex in Duchenne muscular dystrophy. Am. J. Neuroradiol. 2011, 32:2196-2200.
22. Lee J.S., et al. Altered regional brain glucose metabolism in Duchenne muscular dystrophy: a pet study. Muscle Nerve 2002, 26:506-512.
23. Bresolin N., et al. Cognitive impairment in Duchenne muscular dystrophy. Neuromuscul. Disord. 1994, 4:359-369.
24. Tracey I., et al. Brain abnormalities in Duchenne muscular dystrophy: phosphorus-31 magnetic resonance spectroscopy and neuropsychological study. Lancet 1995, 345:1260-1264.
25. Blake D.J., et al. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol. Rev. 2002, 82:291-329.
26. Davies K.E., Nowak K.J. Molecular mechanisms of muscular dystrophies: old and new players. Nat. Rev. Mol. Cell Biol. 2006, 7:762-773.
27. Ervasti J.M. Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim. Biophys. Acta. 2007, 1772:108-117.
28. Wallace G.Q., McNally E.M. Mechanisms of muscle degeneration, regeneration, and repair in the muscular dystrophies. Annu. Rev. Physiol. 2009, 71:37-57.
29. Feener C.A., et al. Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. Nature 1989, 338:509-511.
30. Blake D.J., et al. Characterization of a 4.8kb transcript from the Duchenne muscular dystrophy locus expressed in Schwannoma cells. Hum. Mol. Genet. 1992, 1:103-109.
31. Tadayoni R., et al. Dystrophin dp71: the smallest but multifunctional product of the Duchenne muscular dystrophy gene. Mol. Neurobiol. 2012, 45:43-60.
32. Lidov H.G., et al. Dp140: a novel 140 kDa CNS transcript from the dystrophin locus. Hum. Mol. Genet. 1995, 4:329-335.
33. Byers T.J., et al. An alternative dystrophin transcript specific to peripheral nerve. Nat. Genet. 1993, 4:77-81.
34. D'Souza V.N., et al. A novel dystrophin isoform is required for normal retinal electrophysiology. Hum. Mol. Genet. 1995, 4:837-842.
35. Tinsley J.M., et al. Apo-dystrophin-3: a 2.2 kb transcript from the DMD locus encoding the dystrophin glycoprotein binding site. Hum. Mol. Genet. 1993, 2:521-524.
36. Tozawa T., et al. The shortest isoform of dystrophin (dp40) interacts with a group of presynaptic proteins to form a presumptive novel complex in the mouse brain. Mol. Neurobiol. 2012, 45:287-297.
37. Bushby K.M., et al. Deletion status and intellectual impairment in Duchenne muscular dystrophy. Dev. Med. Child Neurol. 1995, 37:260-269.
38. Taylor P.J., et al. Dystrophin gene mutation location and the risk of cognitive impairment in Duchenne muscular dystrophy. PLoS ONE 2010, 5:e8803.
39. Daoud F., et al. Analysis of Dp71 contribution in the severity of mental retardation through comparison of Duchenne and Becker patients differing by mutation consequences on Dp71 expression. Hum. Mol. Genet. 2009, 18:3779-3794.
40. Blake D.J., et al. Different dystrophin-like complexes are expressed in neurons and glia. J. Cell Biol. 1999, 147:645-658.
41. Piluso G., et al. Gamma1- and gamma2-syntrophins, two novel dystrophin-binding proteins localized in neuronal cells. J. Biol. Chem. 2000, 275:15851-15860.
42. Blake D.J., et al. β-Dystrobrevin, a member of the dystrophin-related protein family. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:241-246.
43. Ervasti J.M., Campbell K.P. Membrane organization of the dystrophin-glycoprotein complex. Cell 1991, 66:1121-1131.
44. Lidov H.G., et al. Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons. Nature 1990, 348:725-728.
45. Knuesel I., et al. Short communication: altered synaptic clustering of GABAA receptors in mice lacking dystrophin (mdx mice). Eur. J. Neurosci. 1999, 11:4457-4462.
46. A receptors and gephyrin. J. Neurosci. 2002, 22:4805-4813.
47. Levi S., et al. Dystroglycan is selectively associated with inhibitory GABAergic synapses but is dispensable for their differentiation. J. Neurosci. 2002, 22:4274-4285.
48. A-receptor clustering in the hippocampus of the mdx mouse. Mol. Ther. 2010, 18:1683-1688.
49. Fritschy J.M., et al. Molecular and functional heterogeneity of GABAergic synapses. Cell Mol. Life Sci. 2012, 10.1007/s00018-012-0926-4.
50. A receptor trafficking-mediated plasticity of inhibitory synapses. Neuron 2011, 70:385-409.
51. Fritschy J.M., et al. Gephyrin: where do we stand, where do we go?. Trends Neurosci. 2008, 31:257-264.
52. Poulopoulos A., et al. Neuroligin 2 drives postsynaptic assembly at perisomatic inhibitory synapses through gephyrin and collybistin. Neuron 2009, 63:628-642.
53. A receptor and gephyrin clustering at perisomatic and axo-axonic synapses on CA1 pyramidal cells. J. Physiol. 2011, 589:4959-4980.
54. Sugita S., et al. A stoichiometric complex of neurexins and dystroglycan in brain. J. Cell Biol. 2001, 154:435-445.
55. Graf E.R., et al. Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cell 2004, 119:1013-1026.
56. Huang X., et al. Structure of a WW domain containing fragment of dystrophin in complex with β-dystroglycan. Nat. Struct. Biol. 2000, 7:634-638.
57. Sumita K., et al. Synaptic scaffolding molecule (S-SCAM) membrane-associated guanylate kinase with inverted organization (MAGI)-2 is associated with cell adhesion molecules at inhibitory synapses in rat hippocampal neurons. J. Neurochem. 2007, 100:154-166.
58. Grady R.M., et al. Cerebellar synaptic defects and abnormal motor behavior in mice lacking α- and β-dystrobrevin. J. Neurosci. 2006, 26:2841-2851.
59. Vaillend C., et al. Genes, plasticity and mental retardation. Behav. Brain Res. 2008, 192:88-105.
60. Sesay A.K., et al. Spatial learning and hippocampal long-term potentiation are not impaired in mdx mice. Neurosci. Lett. 1996, 211:207-210.
61. Vaillend C., et al. Impaired long-term spatial and recognition memory and enhanced CA1 hippocampal LTP in the dystrophin-deficient Dmd (mdx) mouse. Neurobiol. Dis. 2004, 17:10-20.
62. Anderson J.L., et al. Altered inhibitory input to Purkinje cells of dystrophin-deficient mice. Brain Res. 2003, 982:280-283.
63. Anderson J.L., et al. Long-term depression is reduced in cerebellar Purkinje cells of dystrophin-deficient mdx mice. Brain Res. 2004, 1019:289-292.
64. A receptor expression and inhibitory post-synaptic currents in cerebellar Purkinje cells in dystrophin-deficient mdx mice. Clin. Exp. Pharmacol. Physiol. 2008, 35:207-210.
65. A receptor number and enhanced gaboxadol induced change in holding currents in Purkinje cells of the dystrophin-deficient mdx mouse. Neurobiol. Dis. 2011, 43:558-564.
66. Daoud F., et al. Role of mental retardation-associated dystrophin-gene product Dp71 in excitatory synapse organization, synaptic plasticity and behavioral functions. PLoS ONE 2009, 4:e6574.
67. Vaillend C., et al. Influence of dystrophin-gene mutation on mdx mouse behavior. I. Retention deficits at long delays in spontaneous alternation and bar-pressing tasks. Behav. Genet. 1995, 25:569-579.
68. Vaillend C., Ungerer A. Behavioral characterization of mdx3cv mice deficient in C-terminal dystrophins. Neuromuscul. Disord. 1999, 9:296-304.
69. Williamson R.A., et al. Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. Hum. Mol. Genet. 1997, 6:831-841.
70. Satz J.S., et al. Distinct functions of glial and neuronal dystroglycan in the developing and adult mouse brain. J. Neurosci. 2010, 30:14560-14572.
71. Bozzi M., et al. Functional diversity of dystroglycan. Matrix Biol. 2009, 28:179-187.
72. Yoshida A., et al. Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. Dev. Cell 2001, 1:717-724.
73. Yoshida-Moriguchi T., et al. O-Mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science 2010, 327:88-92.
74. Hara Y., et al. A dystroglycan mutation associated with limb-girdle muscular dystrophy. N. Engl. J. Med. 2011, 364:939-946.
75. Godfrey C., et al. Dystroglycanopathies: coming into focus. Curr. Opin. Genet. Dev. 2011, 21:278-285.
76. Muntoni F., et al. Muscular dystrophies due to defective glycosylation of dystroglycan. Acta Myol. 2007, 26:129-135.
77. Willer T., et al. Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:14126-14131.
78. Hu H., et al. Conditional knockout of protein O-mannosyltransferase 2 reveals tissue-specific roles of O-mannosyl glycosylation in brain development. J. Comp. Neurol. 2011, 519:1320-1337.
79. Kurahashi H., et al. Basement membrane fragility underlies embryonic lethality in fukutin-null mice. Neurobiol. Dis. 2005, 19:208-217.
80. Chan Y.M., et al. Fukutin-related protein is essential for mouse muscle, brain and eye development and mutation recapitulates the wide clinical spectrums of dystroglycanopathies. Hum. Mol. Genet. 2010, 19:3995-4006.
81. Ackroyd M.R., et al. Reduced expression of fukutin related protein in mice results in a model for fukutin related protein associated muscular dystrophies. Brain 2009, 132:439-451.
82. Liu J., et al. A genetic model for muscle-eye-brain disease in mice lacking protein O-mannose 1,2-N-acetylglucosaminyltransferase (POMGnT1). Mech. Dev. 2006, 123:228-240.
83. Ackroyd M.R., et al. Fukutin-related protein alters the deposition of laminin in the eye and brain. J. Neurosci. 2011, 31:12927-12935.
84. Pawlisz A.S., Feng Y. Three-dimensional regulation of radial glial functions by Lis1-Nde1 and dystrophin glycoprotein complexes. PLoS Biol. 2011, 9:e1001172.
85. Kerjan G., Gleeson J.G. Genetic mechanisms underlying abnormal neuronal migration in classical lissencephaly. Trends Genet. 2007, 23:623-630.
86. Haenggi T., et al. The role of utrophin and Dp71 for assembly of different dystrophin-associated protein complexes (DPCs) in the choroid plexus and microvasculature of the brain. Neuroscience 2004, 129:403-413.
87. Tian M., et al. Dystroglycan in the cerebellum is a laminin alpha 2-chain binding protein at the glial-vascular interface and is expressed in Purkinje cells. Eur. J. Neurosci. 1996, 8:2739-2747.
88. Vajda Z., et al. Delayed onset of brain edema and mislocalization of aquaporin-4 in dystrophin-null transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:13131-13136.
89. Nicchia G.P., et al. Dystrophin-dependent and -independent AQP4 pools are expressed in the mouse brain. Glia 2008, 56:869-876.
90. Amiry-Moghaddam M., et al. An α-syntrophin-dependent pool of AQP4 in astroglial end-feet confers bidirectional water flow between blood and brain. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:2106-2111.
91. Noell S., et al. Evidence for a role of dystroglycan regulating the membrane architecture of astroglial endfeet. Eur. J. Neurosci. 2011, 33:2179-2186.
92. Jarius S., Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat. Rev. Neurol. 2010, 6:383-392.
93. Sandona D., Betto R. Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects. Expert Rev. Mol. Med. 2009, 11:e28.
94. Ozawa E., et al. Molecular and cell biology of the sarcoglycan complex. Muscle Nerve 2005, 32:563-576.
95. Zimprich A., et al. Mutations in the gene encoding e{open}-sarcoglycan cause myoclonus-dystonia syndrome. Nat. Genet. 2001, 29:66-69.
96. Allikian M.J., McNally E.M. Processing and assembly of the dystrophin glycoprotein complex. Traffic 2007, 8:177-183.
97. Esapa C.T., et al. SGCE missense mutations that cause myoclonus-dystonia syndrome impair e{open}-sarcoglycan trafficking to the plasma membrane: modulation by ubiquitination and torsinA. Hum. Mol. Genet. 2007, 16:327-342.
98. Waite A., et al. A gain-of-glycosylation mutation associated with myoclonus-dystonia syndrome affects trafficking and processing of mouse e{open}-sarcoglycan in the late secretory pathway. Hum. Mutat. 2011, 32:1246-1258.
99. Hjermind L.E., et al. No muscle involvement in myoclonus-dystonia caused by e{open}-sarcoglycan gene mutations. Eur. J. Neurol. 2008, 15:525-529.
100. Breakefield X.O., et al. The pathophysiological basis of dystonias. Nat. Rev. 2008, 9:222-234.
101. Chan P., et al. e{open}-Sarcoglycan immunoreactivity and mRNA expression in mouse brain. J. Comp. Neurol. 2005, 482:50-73.
102. Nishiyama A., et al. Identification and characterization of e{open}-sarcoglycans in the central nervous system. Brain Res. Mol. Brain Res. 2004, 125:1-12.
103. Beukers R.J., et al. Reduced striatal D2 receptor binding in myoclonus-dystonia. Eur. J. Nucl. Med. Mol. Imaging 2009, 36:269-274.
104. Yokoi F., et al. Myoclonus, motor deficits, alterations in emotional responses and monoamine metabolism in e{open}-sarcoglycan deficient mice. J. Biochem. 2006, 140:141-146.
105. Fukaya M., et al. SynArfGEF is a guanine nucleotide exchange factor for Arf6 and localizes preferentially at post-synaptic specializations of inhibitory synapses. J. Neurochem. 2011, 116:1122-1137.
106. Moore C.J., Winder S.J. Dystroglycan versatility in cell adhesion: a tale of multiple motifs. Cell Commun. Signal. 2010, 8:3.
107. Waite A., et al. The neurobiology of the dystrophin-associated glycoprotein complex. Ann. Med. 2009, 41:344-359.
108. Godfrey C., et al. Refining genotype phenotype correlations in muscular dystrophies with defective glycosylation of dystroglycan. Brain 2007, 130:2725-2735.
109. Brockington M., et al. Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin α2 deficiency and abnormal glycosylation of α-dystroglycan. Am. J. Hum. Genet. 2001, 69:1198-1209.
110. Kobayashi K., et al. An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy. Nature 1998, 394:388-392.
111. Topaloglu H., et al. FKRP gene mutations cause congenital muscular dystrophy, mental retardation, and cerebellar cysts. Neurology 2003, 60:988-992.
112. Inamori K., et al. Dystroglycan function requires xylosyl- and glucuronyltransferase activities of LARGE. Science 2012, 335:93-96.
113. Barresi R., et al. LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat. Med. 2004, 10:696-703.
114. Akasaka-Manya K., et al. Physical and functional association of human protein O-mannosyltransferases 1 and 2. J. Biol. Chem. 2006, 281:19339-19345.
115. Peall K.J., et al. Psychiatric disorders, myoclonus dystonia, and the e{open}-sarcoglycan gene: a systematic review. Mov. Disord. 2011, 26:1939-1942.
116. Phukan J., et al. Primary dystonia and dystonia-plus syndromes: clinical characteristics, diagnosis, and pathogenesis. Lancet Neurol. 2011, 10:1074-1085.